VNOV · VitaNova Life Sciences Corp
Market Cap
$11.51M
Shares
8.34M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$3.03M
+13.7%
FY2026
Net Income
-$37.3K
-104.4%
FY2026
Gross Margin
30.1%
-29.1pp
FY2026
Operating Margin
0.12%
-45.3pp
FY2026
Diluted EPS
$0.09
+200%
FY2025
Operating Cash Flow
$814.41K
+322.5%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| — | $3.03M | $2.66M | $570.69K | $38K | $120K | $0 | $0 | $0 | $0 | |
| — | $2.11M | $1.09M | $192.98K | $0 | — | — | — | $0 | $0 | |
| — | $910.59K | $1.58M | $377.71K | $38K | — | — | — | $0 | $0 | |
| — | 30.1% | 59.19% | 66.18% | 100% | — | — | — | — | — | |
| — | $733.8K | $158.12K | $86.75K | $62.23K | $133.37K | $52.09K | $72.33K | $71.81K | $48.65K | |
| — | $906.99K | $367.4K | $172.08K | $62.23K | $133.37K | $52.09K | $72.33K | $71.81K | $48.65K | |
| — | $3601 | $1.21M | $205.63K | -$24.23K | -$13.37K | -$52.09K | -$72.33K | -$71.81K | -$48.65K | |
| — | 0.12% | 45.39% | 36.03% | -63.76% | -11.14% | — | — | — | — | |
| — | $0 | $4506 | $0 | — | — | — | — | — | — | |
| — | $2980 | -$4010 | $105 | $0 | — | — | — | — | — | |
| — | $6581 | $1.2M | $205.73K | -$24.23K | $139.68K | -$52.09K | -$72.33K | -$71.81K | — | |
| — | $43.89K | $353.56K | $64.87K | $0 | $0 | $0 | $0 | $0 | $0 | |
| — | -$37.3K | $850.75K | $140.87K | -$24.23K | $139.68K | -$52.09K | -$72.33K | -$106.17K | -$1595 | |
| — | -1.23% | 31.96% | 24.68% | -63.76% | 116.4% | — | — | — | — | |
| USD/shares | — | -$0.00 | $0.10 | $0.03 | $0.00 | $0.06 | -$0.03 | — | — | — |
| USD/shares | $0.07 | — | $0.09 | $0.03 | $0.00 | $0.06 | -$0.03 | — | — | — |
| shares | — | 8.34M | 8.34M | 3.55M | 1.96M | 1.96M | 1.96M | 1.96M | 1.96M | 1.61M |
| shares | — | — | 8.34M | 3.55M | 1.96M | 1.96M | 1.96M | 1.96M | 1.96M | 1.61M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Medical Distribution median 0.35×
EV/EBIT
—
Medical Distribution median 17.89×
P/E (TTM)
—
Medical Distribution median 24.39×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Dietary Supplement Segment | $1,947,620 | $2,651,267 | — | — |
| Food Products | $1,062,918 | — | — | — |
| Other | $15,000 | — | — | — |
| Consulting Service Segment | — | $10,838 | $26,100 | $38,000 |
| Healthcare Segment | — | — | $544,594 | $0 |
By Geography (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Unites States Of America | $2,679,960 | $1,204,157 | $77,849 | $38,000 |
| Hong Kong SAR China | $345,578 | $1,072,230 | $81,745 | $0 |
| China | $0 | $385,718 | $411,100 | $0 |
By Product & Service (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Dietary Supplement Products | $1,947,620 | $2,651,267 | — | — |
| Sale of Food Products | $1,062,918 | — | — | — |
| Consulting Service Income | $15,000 | $10,838 | $26,100 | $38,000 |
| Sale of Healthcare Products | — | — | $544,594 | — |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Dietary Supplement Segment | $168,067 | $1,479,030 | — | — |
| Other | $15,000 | — | — | — |
| Food Products | -$179,466 | — | — | — |
| Consulting Service Segment | — | -$270,716 | -$103,273 | -$24,227 |
| Healthcare Segment | — | — | $308,902 | $0 |
Operating Margin by Segment (%)
| Component | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Dietary Supplement Segment | 8.6% | 55.8% | — | — |
| Food Products | -16.9% | — | — | — |
| Other | 100% | — | — | — |
| Consulting Service Segment | — | -2497.8% | -395.7% | -63.8% |
| Healthcare Segment | — | — | 56.7% | — |
Key facts
CIK
1699709